Plasmablastic lymphoma: A review of current knowledge and future directions

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Elyamany G.; Al Mussaed E.; Alzahrani A.M.

Journal: Advances in Hematology

Publisher: John Wiley and Sons Ltd

Publication Date: 2015

Volume / Issue: Volume 2015

Article No.: 315289

ISSN: 16879104

DOI: 10.1155/2015/315289

Scopus: View on Scopus

Document Type: Retracted

Access: All Open Access; Gold Open Access; Green Open Access


Authors and Affiliations

Elyamany G., Department of Pathology and Blood Bank, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh, 11159, Saudi Arabia, Department of Hematology, Theodor Bilharz Research Institute, Egypt; Al Mussaed E., Hematopathology Division, Department of Basic Science, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia; Alzahrani A.M., Department of Oncology, Prince Sultan Military Medical City, Saudi Arabia


Abstract

Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells. PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma (PCM). PBL is also a therapeutic challenge with a clinical course characterized by a high rate of relapse and death. There is no standard chemotherapy protocol for treatment of PBL. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens have been the backbone while more intensive regimens such as cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, high-dose cytarabine (CODOX-M/IVAC), or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) are possible options. Recently, a few studies have reported the potential value of the proteasome inhibitor bortezomib and thalidomide in PBL patients. The introduction of genes encoding artificial receptors called chimeric antigen receptors (CARs) and CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials. The aim of this paper is to review the recent advances in epidemiology; pathophysiology; clinical, pathologic, and molecular characteristics; therapy; and outcome in patients with PBL. © 2015 Ghaleb Elyamany et al.


Keywords

CD19 antigen; chimeric antigen receptor; cyclophosphamide; cytarabine; doxorubicin; etoposide; ifosfamide; methotrexate; prednisone; vincristine; autologous hematopoietic stem cell transplantation; B lymphocyte; biopsy; cancer combination chemotherapy; cancer diagnosis; cancer epidemiology; cancer prevention; cancer prognosis; cell proliferation; differential diagnosis; drug megadose; fine needle aspiration biopsy; human; immunophenotyping; overall survival; pathogenesis; pathophysiology; plasmablastic lymphoma; priority journal; Review; T lymphocyte; treatment outcome


Citation Information

Scopus Citations: 32


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects